Phase I Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of NDV-3, a Recombinant Alum-Adjuvanted Vaccine for Staphylococcus Aureus and Candida Infections, Administered Intramuscular to Healthy Adults.
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2012
At a glance
- Drugs NDV 3 (Primary)
- Indications Candidiasis; Staphylococcal infections
- Focus Adverse reactions
- 13 Dec 2012 Results published in Vaccine, according to a NovaDigm Therapeutics media release.
- 21 May 2012 Actual end date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 20 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.